Revlimid fades, semaglutide must prove itself
- The main test is whether new products can offset the active Revlimid patent cliff.
- FY2026 adjusted revenue was $3.63 billion, with adjusted EBITDA margin of 24.7%.
- Semaglutide is now approved in Canada and India, shifting the risk from approval to launch pricing.
- Abatacept IV was filed in December 2025 and accepted by the FDA in February 2026.
- The balance sheet gives room to work, with a $349 million net cash surplus at March 31, 2026.
A bridge after Revlimid
Dr. Reddy's is in a hard handoff. Generic Revlimid, also called lenalidomide, was a major profit source, but its January 2026 patent cliff is now active. North America is already feeling that pressure.
The bull case is that management has real tools to cross the gap. The NRT consumer health deal has lifted Europe, semaglutide is approved in Canada and India for type 2 diabetes, and the Abatacept IV biosimilar filing was accepted by the FDA. Those are not small milestones.
The bear case is that each bridge piece still has to earn its keep. Generic GLP-1 drugs such as semaglutide can get crowded fast, and management itself framed a likely floor near $25 to $30 in some markets. Biosimilars can be large, but past CRLs for rituximab and partner Alvotech's denosumab show that approval is not automatic.
Finn's view is mixed but not negative. The stock has a decent valuation setup and sound balance sheet, while performance and sentiment are held back by the Revlimid drop, quality watch items, and launch risk.
Generics cash, harder launches
Dr. Reddy's makes money by selling generic medicines around the world. It also sells active pharmaceutical ingredients, the chemical building blocks inside drugs, and does some CDMO work, which means manufacturing or development work for other drug companies.
The old model leaned on broad generic scale, especially in North America. The newer model aims for higher-value areas: consumer health through nicotine replacement therapy, complex generics like semaglutide, innovative products in India and emerging markets, and biosimilars.
Management wants double-digit sales growth and about 25% EBITDA margin over time. FY2026 adjusted EBITDA margin was 24.7%, but Q4 was closer to 19.5% on adjusted revenue after the Revlimid reset. Management has also pointed to a 500 to 600 basis point discretionary cost lever in SG&A and R&D if margins need defense.
This model breaks if new launches arrive late, price too low, or fail inspection. It also breaks if the base U.S. generic business keeps eroding faster than Europe, India, emerging markets, and PSAI can grow.
What fills the medicine cabinet
Global generics
This is the core business: copies of branded drugs sold after patent protection fades. North America remains important, but it is under pressure from Revlimid erosion and normal generic price cuts.
Lenalidomide, generic Revlimid
Lenalidomide has been a major contributor, but the patent cliff is now active. Q4 FY2026 included a shelf-stock adjustment tied to this product, which makes the drop very visible.
Nicotine replacement therapy consumer health
The acquired NRT business gives Dr. Reddy's a consumer health leg in Europe. Management said integration is largely complete and expects the business to grow above its original mid-single-digit view.
Semaglutide
This is the key complex generic launch. It is approved in Canada and India for type 2 diabetes, and management is targeting calendar 2026 launches across approved markets, with pricing risk still central.
Abatacept biosimilar
The IV version was filed in December 2025 and accepted by the FDA in February 2026. Management points to a likely early calendar 2027 launch if approval and inspections go well.
Other biosimilars and partnerships
The company has partnered assets such as denosumab and a collaboration with Alvotech for pembrolizumab. These can be large, but CRLs and deficiency letters show that the path is uneven.
India brands and in-licensed products
India is growing double digits, helped by launches, price increases, volume, and selected brand deals. The business also includes in-licensed vaccines and innovative products.
Where sales come from
The mix uses FY2026 revenue disclosed on the May 12, 2026 earnings call, converted with management's stated INR 93.83 convenience rate where needed. North America is the largest bucket, but it is also the one most exposed to Revlimid.
What can still break
Revlimid cliff cuts deeper
High impact · High oddsThe January 2026 Revlimid cliff is no longer a future worry. North America revenue fell because of lenalidomide, and Q4 included a shelf-stock adjustment tied to the product. If the base U.S. business does not grow fast enough, margin pressure can linger.
Semaglutide price war
High impact · Medium oddsSemaglutide approval in Canada and India lowers approval risk, but the real test is market formation. Management expects Canada to be competitive and framed some prices around $25 to $30, with higher prices in some markets. More entrants or an authorized generic from Novo could push realized prices below plan.
India semaglutide IP loss
Medium impact · Medium oddsDr. Reddy's launched semaglutide in India, but the company has also been challenging patents in the Delhi High Court. A bad ruling could limit sales or change launch economics. That would matter because India is one of the approved early markets.
Biosimilar approval delays
High impact · Medium oddsBiosimilars are a big part of the post-Revlimid plan, especially Abatacept. The IV BLA is accepted for review, but inspections and final FDA decisions still matter. CRLs for rituximab and partner Alvotech's denosumab show that setbacks are possible.
Quality and tariff pressure
Medium impact · Medium oddsRecent FDA inspections produced Form 483 observations, though Srikakulam FTO 11 received VAI classification. Potential U.S. generic or API tariffs could also hurt supply chains and margins. A U.S. CMO for Abatacept helps, but it does not remove the whole risk.
In one breath
What does Dr. Reddy's Laboratories do?
Dr. Reddy's sells generic medicines, active pharmaceutical ingredients, consumer health products, and biosimilars. Its main markets include North America, Europe, India, and emerging markets.
Why does Revlimid matter so much for RDY?
Revlimid is the branded drug name for lenalidomide, and Dr. Reddy's generic version was a major contributor. The patent cliff began in January 2026, so more competition and lower prices are now pressuring North America sales.
Is semaglutide already approved for Dr. Reddy's?
Yes, the injectable semaglutide product for type 2 diabetes is approved in Canada and India. The next question is not only approval, but how many pens sell and at what price as more competitors enter.
What is the next big catalyst for RDY?
Semaglutide launches across Canada and other approved markets are the near-term focus in calendar 2026. Abatacept IV has an FDA review underway, with management pointing to a likely early calendar 2027 launch if approval is received.